Everything drug pricing and policy, every day
And Hims announced a compounded version of Wegovy’s active ingredient, causing reactions from Novo and the FDA
And Express Scripts settles with the FTC, with the PBM promising to fundamentally change its business practices
But today big stories all involve obesity-med dynamics, and I’ll go deep there in tomorrow’s Apex
PBM reform is getting close to the congressional finish line, but questions remain about the impact
And it’s a quiet day -- but probably a noisy week -- when it comes to drug-pricing news
And the White House wants Congress to codify its MFN policies. Republicans are (appropriately) skeptical.
And there’s reporting that the launch of TrumpRx is imminent, though questions persist
And HHS is working to identify and limit legal risks around TrumpRx and other pharm-to-table programs
And hospitals strike back as Lilly moves to require more data from in-house pharmacies at 340B providers
